In a study of 92 patients with NSCLC receiving the anti-PD1 mAb nivolumab,123 detection of more than one of autoantibodies (including ANA, ENAs and ASMA) within 30 days of starting therapy was correlated with the risk of irAEs (P = 0.002). Here, PDCD1 is linked to non-small cell lung carcinoma.